TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,008 | -85.7% | 13,200 | -75.4% | 0.00% | -100.0% |
| Q2 2023 | $823,296 | -89.6% | 53,600 | -84.8% | 0.00% | -88.9% |
| Q1 2023 | $7,934,180 | +39.1% | 352,787 | +30.1% | 0.03% | +28.6% |
| Q4 2022 | $5,703,588 | -58.1% | 271,212 | -51.0% | 0.02% | -22.2% |
| Q3 2022 | $13,625,886 | +22.2% | 552,994 | +20.2% | 0.03% | +28.6% |
| Q2 2022 | $11,150,081 | +19.1% | 460,180 | +26.7% | 0.02% | +61.5% |
| Q1 2022 | $9,361,682 | +1309.9% | 363,266 | +1597.5% | 0.01% | +550.0% |
| Q4 2021 | $664,000 | -84.2% | 21,400 | -92.6% | 0.00% | -66.7% |
| Q2 2021 | $4,200,000 | -48.0% | 287,800 | -11.1% | 0.01% | -76.0% |
| Q1 2021 | $8,083,000 | +55.9% | 323,718 | +70.2% | 0.02% | +56.2% |
| Q4 2020 | $5,184,000 | – | 190,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |